The journey of remdesivir: from Ebola to COVID-19.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing preclinical and preliminary clinical evidence without systematic methodology.
PubMed 32547625 · doi:10.7573/dic.2020-4-14
What was done
This narrative review summarizes preclinical and clinical investigations of the broad-spectrum antiviral remdesivir (GS-5734), tracing its development and evaluation from Ebola virus outbreaks to its repurposing for SARS-CoV-2 during the early phase of the COVID-19 pandemic.
What was found
The abstract reports no numerical data. It notes that remdesivir showed preclinical efficacy but failed to meet efficacy endpoints in a randomized trial for Ebola. For COVID-19, evidence was confined to in vitro activity against SARS-CoV-2, uncontrolled clinical reports, and limited preliminary randomized trial data, which the authors concluded were insufficient to establish therapeutic efficacy.
Why it matters
The paper captures the early-pandemic clinical landscape and translational rationale for repurposing remdesivir, highlighting the gap between in vitro antiviral activity and proven clinical benefit.
Limits
The paper is a non-systematic narrative review providing no quantitative synthesis. The underlying clinical evidence base available at the time was highly preliminary, relying heavily on in vitro studies and uncontrolled clinical series rather than completed, robust randomized controlled trials.
Cited by
- supports Remdesivir was originally developed as a treatment for Ebola.